Emergency Department Management of Patients With Sickle Cell Disease

CME Information

Date of Original Release: August 1, 2024. Date of most recent review: July 10, 2024. Termination date: August 1, 2027.

Accreditation: EB Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation: EB Medicine designates this enduring material for a maximum of 4 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Specialty CME: Not applicable. For more information, call Customer Service at 678-366-7933.

ACEP Accreditation: Emergency Medicine Practice is approved by the American College of Emergency Physicians for 48 hours of ACEP Category I credit per annual subscription.

AAFP Accreditation: The AAFP has reviewed Emergency Medicine Practice, and deemed it acceptable for AAFP credit. Term of approval is from 07/01/2025 to 06/30/2026. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This session, Emergency Department Management of Patients With Sickle Cell Disease, is approved for 4.0 enduring material AAFP Prescribed credits.

AOA Accreditation: Emergency Medicine Practice is eligible for 4 Category 2-B credit hours per issue by the American Osteopathic Association.

Needs Assessment: The need for this educational activity was determined by a practice gap analysis; a survey of medical staff, including the editorial board of this publication; review of morbidity and mortality data from the CDC, AHA, NCHS, and ACEP; and evaluation responses from prior educational activities for emergency physicians.

Target Audience: This enduring material is designed for emergency medicine physicians, physician assistants, nurse practitioners, and residents.

Goals: Upon completion of this activity, you should be able to: (1) identify areas in practice that require modification to be consistent with current evidence in order to improve competence and performance; (2) develop strategies to accurately diagnose and treat both common and critical ED presentations; and (3) demonstrate informed medical decision-making based on the strongest clinical evidence.

CME Objectives: Upon completion of this activity, you should be able to: (1) outline the etiologies of the common acute complications of sickle cell disease; (2) select the safest and most effective pain management strategies, based on current evidence; and (3) describe recommended treatments for acute complaints associated with sickle cell disease.

Discussion of Investigational Information: As part of the activity, faculty may be presenting investigational information about pharmaceutical products that is outside Food and Drug Administration approved labeling. Information presented as part of this activity is intended solely as continuing medical education and is not intended to promote off-label use of any pharmaceutical product.

Disclosure: It is the policy of EB Medicine to ensure objectivity, balance, independence, transparency, and scientific rigor in all CME activities. All individuals in a position to control content have disclosed all financial relationships with ACCME-defined ineligible companies. EB Medicine has assessed all relationships with ineligible companies disclosed, identified those financial relationships deemed relevant, and appropriately mitigated all relevant financial relationships based on each individual’s role(s). Please find disclosure information for this activity below:

Planners

• Daniel J. Egan, MD (Course Director): Has no relevant relationships with ineligible companies.
• Andy Jagoda, MD (Editor-in-Chief):
  • Pfizer (Consultant/Advisor)
  • Johnson & Johnson (Consultant/Advisor)
  • Indivior (Consultant/Advisor)
  • AstraZeneca (Consultant/Advisor)
• Kaushal Shah, MD (Associate Editor-in-Chief): Has no relevant relationships with ineligible companies.

Faculty

• Babette Newman, DO (Author): Has no relevant relationships with ineligible companies.
• R. Gentry Wilkerson, MD (Author):
  • CoapTech (research support/funding)
  • Global Blood Therapeutics (research support/funding)
  • Novartis (research support/funding)
  • CSL Behring (research support/funding)
  • Roche (research support/funding)
  • Vapotherm (research support/funding)
  • Becton Dickinson (research support/funding)
• Caroline Freiermuth, MD, MHS (Peer Reviewer): Has no relevant relationships with ineligible companies.
• Angela Hua, MD (Peer Reviewer): Has no relevant relationships with ineligible companies.
• Aimee Mishler, PharmD (Pharmacology Editor): Has no relevant relationships with ineligible companies.
• Joseph D. Toscano, MD (Research Editor): Has no relevant relationships with ineligible companies.
• Dorothy Whisenhunt, MS (Content Editor): Has no relevant relationships with ineligible companies.
• Cheryl Belton, PhD (Content Editor): Has no relevant relationships with ineligible companies.

Earning Credit: Learners can earn credit by going to www.ebmedicine.net and selecting the test they wish to complete. To receive credit, they must score 100% on the test and complete the evaluation. After completing these steps, a CME certificate will be emailed to them.  

Additional Policies: For additional policies, including our statement of conflict of interest, source of funding, statement of informed consent, and statement of human and animal rights, visit https://www.ebmedicine.net/policies.